Bausch + Lomb Corp stock (CA07174N1090): valuation metrics in focus after recent trading in Toronto and New York

Bausch + Lomb Corp shares continue to trade actively in Canada and the United States, with recent prices around the low-20s Canadian dollars on the TSX and mid-teens US dollars on the NYSE shaping key valuation ratios ahead of the next earnings update.

Bausch + Lomb Corp shares were recently quoted around the low-20s Canadian dollars on the Toronto Stock Exchange and in the mid-teens US dollars on the New York Stock Exchange, keeping the Canadian eye-care group in focus for valuation-driven investors as trading activity continued in early June 2026, according to Investing.com on 06/05/2026 and Robinhood on 06/05/2026.

According to Investing.com, Bausch + Lomb Corp traded at approximately CAD 21.25 on the Toronto Stock Exchange on 06/05/2026, which implies a modest upside relative to a compared fair value indication of CAD 21.64 on the same date, underlining how the stock is being priced in its home Canadian market.

In the United States, Robinhood data as of 06/05/2026 showed Bausch + Lomb Corp at USD 15.35 per share with a market capitalization of about USD 5.47 billion and a stated price-to-earnings ratio of around -24.84, highlighting that the group is currently loss-making on a trailing earnings basis while maintaining a multi-billion-dollar equity valuation.

The home-country hook is important because Bausch + Lomb Corp is headquartered in Canada and lists its shares on the Toronto Stock Exchange under the ticker BLCO, even though the company also maintains a prominent listing and active trading presence on the New York Stock Exchange for US-based investors.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bausch + Lomb Corp
• Sector/industry: Eye health, medical devices, pharmaceuticals
• Headquarters/country: Vaughan, Canada
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Vision care products, ophthalmic pharmaceuticals, surgical eye-care devices
• Home exchange/listing venue: Toronto Stock Exchange (BLCO)
• Trading currency: CAD

Bausch + Lomb Corp: core business model

Bausch + Lomb focuses on developing and supplying a broad portfolio of eye-care products, with revenue closely tied to demand for contact lenses, lens-care solutions, ophthalmic drugs and surgical equipment used by eye-care professionals worldwide.

Valuation metrics and multiples for Bausch + Lomb Corp

From a valuation perspective, Robinhood reported on 06/05/2026 that Bausch + Lomb Corp was trading at USD 15.35 per share with a market capitalization of about USD 5.47 billion and a price-to-earnings ratio of approximately -24.84, confirming that the company is currently valued on expectations of future profitability rather than on positive trailing earnings.

Investing.com data for 06/05/2026 indicated a Toronto Stock Exchange price of roughly CAD 21.25 and an implied fair value comparison of CAD 21.64, suggesting that the stock was trading slightly below this specific valuation marker while still reflecting the company’s established position in the global eye-health sector.

Conclusion

Recent trading data on 06/05/2026 from Investing.com and Robinhood indicate that Bausch + Lomb Corp continues to change hands around CAD 21.25 in Toronto and USD 15.35 in New York, anchoring the company’s valuation at roughly USD 5.47 billion despite negative trailing earnings.

These price levels translate into a negative price-to-earnings ratio of about -24.84, underscoring that investors are valuing the Canadian eye-care specialist primarily on the basis of its strategic positioning and potential future profitability rather than current net income.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.